INTERPHARM WARNED THAT FAILURE TO CORRECT GMP VIOLATIONS
This article was originally published in The Tan Sheet
INTERPHARM WARNED THAT FAILURE TO CORRECT GMP VIOLATIONS could trigger the provisions of a recent consent decree, FDA told the company in an Aug. 31 warning letter. Failure "to correct these deviations...may result in regulatory action without further notice. Possible actions include seizure and/or the implementation of the terms of the consent decree of permanent injunction which was ordered by the [Federal] Court in the District of Maryland on Aug. 16, 1994," the warning letter states.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC